Your Screens
the ones you keep on the screenerReady-made Screens It Passes
each filter against AAREYDRUGS's own figureAAREYDRUGS passes none of the ready-made screens today.
One or two filters away
which filter, and by how muchRevenue and profit both growing 15%+Misses 1 of 2
476 companies pass it today · see them →
revenue growth at least 15%-7.7%
profit growth at least 15%17.5%
Profitable, dividend yield above 3%Misses 1 of 2
92 companies pass it today · see them →
made a profit over the last four quarters₹5 Cr
dividend yield at least 3%no dividend in the last year
Profitable, priced below book valueMisses 1 of 2
262 companies pass it today · see them →
made a profit over the last four quarters₹5 Cr
P/B at most 11.9
Near its 52-week high, above ₹5,000 CrMisses 1 of 2
123 companies pass it today · see them →
within 10% of its 52-week high98% of the way up
market cap at least ₹5,000 Cr₹289 Cr
Top 100 by size, ROE above 15%Misses 2 of 3
59 companies pass it today · see them →
top 100 by market cap#1953
made a profit over the last four quarters₹5 Cr
ROE at least 15%3.2%
P/E under 15, market cap above ₹1,000 CrMisses 2 of 3
249 companies pass it today · see them →
made a profit over the last four quarters₹5 Cr
P/E at most 1559.2
market cap at least ₹1,000 Cr₹289 Cr
4 other ready-made screens it misses on every filter or on more than two. All screens →
AAREYDRUGS Figuresrebuilt 26 Sept
Market cap₹289 Cr
Rank by market cap#1953
P/E59.2
P/B1.9
ROE3.2%
Debt to equity0.33
Revenue growth-7.7%
Profit growth17.5%
Net margin1.2%
Dividend yieldno dividend in the last year
Place in its 52-week range98% of the way up
Below its 52-week high1.0%
Daily turnover₹2 Cr
The last four quarters of filings, consolidated where the company files it, and our end-of-day closes. These are the numbers every filter on this page is held against.
Write Your Own
A screen is a line of English: “debt free with roe above 20%”. Keep one, and it is run again every night; this page then shows whether AAREYDRUGS passes it.
Open the screener →